SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
The Subject Expert Committee (SEC), that advises the Central drug regulator regarding clinical trials and approvals of drugs, has recommended for grant of permission to Dr Reddy's Laboratories to import and market cancer drug toripalimab 240 mg solution for infusion with waiver of local phase III clinical trial, subject to conditions.
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
SHANGHAI, China, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
SHANGHAI, China, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (œJunshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
SHANGHAI, China, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (œJunshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
INOVIO and Coherus Announce Clinical Collaboration
SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with...